$IBIO
iBio, Inc. Stock $ibio

$ibio Overview Financials Valuation SEC Filings Company Website

2017 Q1 Form 10-Q Financial Statement

#000114420417010136 Filed on February 21, 2017

Income Statement

Concept	2017 Q1	2016 Q4	2016 Q2
Revenue	$37.00K	$75.00K	$280.0K
YoY Change	-90.24%	-44.03%	-12.5%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$2.840M	$2.350M	$2.180M
YoY Change	18.33%	39.88%	50.34%
% of Gross Profit
Research & Development	$1.136M	$1.049M	$850.0K
YoY Change	8.4%	49.01%	11.84%
% of Gross Profit
Depreciation & Amortization	$337.0K	$326.0K	$410.0K
YoY Change	29.12%	32500.0%	310.0%
% of Gross Profit
Operating Expenses	$3.973M	$3.400M	$3.030M
YoY Change	15.13%	42.38%	37.1%
Operating Profit	-$3.936M	-$3.325M
YoY Change	28.13%	47.52%
Interest Expense	$481.0K	$483.0K	-$470.0K
YoY Change	48.92%
% of Operating Profit
Other Income/Expense, Net	-$469.0K	-$467.0K	$0.00
YoY Change	49.84%	-5937.5%	-100.0%
Pretax Income	-$4.410M	-$3.790M	-$3.220M
YoY Change	30.09%	68.44%	70.37%
Income Tax			$0.00
% Of Pretax Income
Net Earnings	-$3.913M	-$3.229M	-$2.680M
YoY Change	28.89%	43.77%	41.8%
Net Earnings / Revenue	-10575.68%	-4305.33%	-957.14%
Basic Earnings Per Share
Diluted Earnings Per Share	-$438.8K	-$362.5K	-$304.2K
COMMON SHARES
Basic Shares Outstanding	89.11M shares	89.11M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2017 Q1	2016 Q4	2016 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments	$12.42M	$16.33M	$23.01M
YoY Change	-43.26%	142.64%	142.47%
Cash & Equivalents	$12.42M	$16.33M	$23.01M
Short-Term Investments
Other Short-Term Assets	$370.0K	$290.0K	$260.0K
YoY Change	15.63%	16.0%	1429.41%
Inventory	$60.00K	$30.00K	$20.00K
Prepaid Expenses
Receivables	$130.0K	$25.00K	$484.0K
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$12.98M	$16.75M	$23.91M
YoY Change	-42.87%	132.58%	136.2%
LONG-TERM ASSETS
Property, Plant & Equipment	$25.79M	$25.45M	$25.57M
YoY Change	0.07%	181707.14%	196623.08%
Goodwill
YoY Change
Intangibles	$1.895M	$1.960M	$2.092M
YoY Change	-11.41%	-10.95%	-11.36%
Long-Term Investments
YoY Change
Other Assets	$30.00K	$30.00K	$30.00K
YoY Change	0.0%
Total Long-Term Assets	$27.72M	$27.44M	$27.69M
YoY Change	-0.81%	1138.83%	1067.05%
TOTAL ASSETS
Total Short-Term Assets	$12.98M	$16.75M	$23.91M
Total Long-Term Assets	$27.72M	$27.44M	$27.69M
Total Assets	$40.70M	$44.19M	$51.60M
YoY Change	-19.67%	369.29%	313.0%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$1.390M	$731.0K	$1.177M
YoY Change	-10.38%	-45.2%	6.61%
Accrued Expenses	$960.0K	$905.0K	$920.0K
YoY Change	47.69%	381.38%	478.62%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$180.0K	$180.0K	$170.0K
YoY Change	5.88%
Total Short-Term Liabilities	$2.621M	$1.867M	$2.291M
YoY Change	7.37%	21.23%	81.39%
LONG-TERM LIABILITIES
Long-Term Debt	$25.13M	$25.18M	$25.27M
YoY Change	-0.71%
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities	$25.13M	$25.18M	$25.27M
YoY Change	-0.71%
TOTAL LIABILITIES
Total Short-Term Liabilities	$2.621M	$1.867M	$2.291M
Total Long-Term Liabilities	$25.13M	$25.18M	$25.27M
Total Liabilities	$27.75M	$27.04M	$27.56M
YoY Change	0.0%	1658.26%	2081.79%
SHAREHOLDERS EQUITY
Retained Earnings	-$67.79M	-$63.88M	-$57.59M
YoY Change		23.14%	20.42%
Common Stock	$80.77M	$68.06M	$67.56M
YoY Change	27.78%	13.84%	14.34%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$12.95M	$4.153M	$9.937M
YoY Change
Total Liabilities & Shareholders Equity	$40.70M	$44.19M	$51.60M
YoY Change	-19.68%	369.29%	313.0%

Cashflow Statement

Concept	2017 Q1	2016 Q4	2016 Q2
OPERATING ACTIVITIES
Net Income	-$3.913M	-$3.229M	-$2.680M
YoY Change	28.89%	43.77%	41.8%
Depreciation, Depletion And Amortization	$337.0K	$326.0K	$410.0K
YoY Change	29.12%	32500.0%	310.0%
Cash From Operating Activities	-$3.560M	-$3.570M	-$2.820M
YoY Change	45.9%	115.06%	133.06%
INVESTING ACTIVITIES
Capital Expenditures	-$300.0K	-$170.0K	-$60.00K
YoY Change		-1800.0%	-14.29%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities	-$300.0K	-$170.0K	-$60.00K
YoY Change		-1800.0%	-14.29%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-50.00K	-40.00K	4.000M
YoY Change	-100.28%		48.15%
NET CHANGE
Cash From Operating Activities	-3.560M	-3.570M	-2.820M
Cash From Investing Activities	-300.0K	-170.0K	-60.00K
Cash From Financing Activities	-50.00K	-40.00K	4.000M
Net Change In Cash	-3.910M	-3.780M	1.120M
YoY Change	-125.79%	129.09%	-21.13%
FREE CASH FLOW
Cash From Operating Activities	-$3.560M	-$3.570M	-$2.820M
Capital Expenditures	-$300.0K	-$170.0K	-$60.00K
Free Cash Flow	-$3.260M	-$3.400M	-$2.760M
YoY Change	33.61%	103.59%	142.11%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	us-gaap	Profit Loss ProfitLoss	-7404000	USD
	us-gaap	Profit Loss ProfitLoss	-4051000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	506000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	643000	USD
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	176000	USD
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	182000	USD
	us-gaap	Depreciation Depreciation	650000	USD
	us-gaap	Depreciation Depreciation	2000	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-459000	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-243000	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	28000	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	70000	USD
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-255000	USD
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	190000	USD
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-15000	USD
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	29000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-5837000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-2814000	USD
	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	226000	USD
	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	0	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	539000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	5000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-765000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-5000	USD
	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	0	USD
	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	63000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	-83000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	63000	USD
	us-gaap	Effect Of Exchange Rate On Cash And Cash Equivalents EffectOfExchangeRateOnCashAndCashEquivalents	0	USD
	us-gaap	Effect Of Exchange Rate On Cash And Cash Equivalents EffectOfExchangeRateOnCashAndCashEquivalents	-6000	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-6685000	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-2762000	USD
CY2016Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	23014000	USD
CY2015Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	9494000	USD
CY2016Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	16329000	USD
CY2015Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	6732000	USD
	us-gaap	Increase Decrease In Unbilled Receivables IncreaseDecreaseInUnbilledReceivables	-47000	USD
	us-gaap	Increase Decrease In Unbilled Receivables IncreaseDecreaseInUnbilledReceivables	15000	USD
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	31000	USD
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	16000	USD
	us-gaap	Interest Paid InterestPaid	966000	USD
	us-gaap	Interest Paid InterestPaid	0	USD
	us-gaap	Increase Decrease In Security Deposits IncreaseDecreaseInSecurityDeposits	1000	USD
	us-gaap	Increase Decrease In Security Deposits IncreaseDecreaseInSecurityDeposits	0	USD
	us-gaap	Increase Decrease In Finished Goods And Work In Process Inventories IncreaseDecreaseInFinishedGoodsAndWorkInProcessInventories	5000	USD
	us-gaap	Increase Decrease In Finished Goods And Work In Process Inventories IncreaseDecreaseInFinishedGoodsAndWorkInProcessInventories	0	USD
	us-gaap	Repayments Of Long Term Capital Lease Obligations RepaymentsOfLongTermCapitalLeaseObligations	83000	USD
	us-gaap	Repayments Of Long Term Capital Lease Obligations RepaymentsOfLongTermCapitalLeaseObligations	0	USD
CY2016Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	1960000	USD
CY2016Q2	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	2092000	USD
CY2016Q4	us-gaap	Capital Leases Future Minimum Payments Due Current CapitalLeasesFutureMinimumPaymentsDueCurrent	2100000	USD
CY2016Q4	us-gaap	Capital Leases Future Minimum Payments Due In Two Years CapitalLeasesFutureMinimumPaymentsDueInTwoYears	2100000	USD
CY2016Q4	us-gaap	Capital Leases Future Minimum Payments Due In Three Years CapitalLeasesFutureMinimumPaymentsDueInThreeYears	2100000	USD
CY2016Q4	us-gaap	Capital Leases Future Minimum Payments Due In Four Years CapitalLeasesFutureMinimumPaymentsDueInFourYears	2100000	USD
CY2016Q4	us-gaap	Capital Leases Future Minimum Payments Due In Five Years CapitalLeasesFutureMinimumPaymentsDueInFiveYears	2100000	USD
CY2016Q4	us-gaap	Capital Leases Future Minimum Payments Due Thereafter CapitalLeasesFutureMinimumPaymentsDueThereafter	59325000	USD
CY2016Q4	us-gaap	Capital Leases Future Minimum Payments Due CapitalLeasesFutureMinimumPaymentsDue	69825000	USD
CY2016Q4	us-gaap	Capital Leases Income Statement Interest Expense CapitalLeasesIncomeStatementInterestExpense	483000	USD
	us-gaap	Capital Leases Income Statement Interest Expense CapitalLeasesIncomeStatementInterestExpense	966000	USD
	ibio	Sub Lease Expiration Period SubLeaseExpirationPeriod	P34Y
	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	2100000	USD
CY2016Q4	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	241000	USD
CY2015Q4	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	314000	USD
CY2015Q4	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-2246000	USD
CY2016Q2	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	484000	USD
CY2016Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	25000	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	506000	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	643000	USD
CY2016Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue	146000	USD
CY2016Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	146000	USD
CY2016Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	12273334	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	0	shares
CY2016Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	12273334	shares
CY2016Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	12241807	shares
CY2016Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	9420029	shares
CY2016Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	1.31
CY2016Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	1.3
CY2016Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice	1.3
CY2016Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	1.3
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1	P5Y2M12D
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1	P5Y10M24D
CY2016	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P6Y4M24D
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P5Y10M24D
CY2016Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	993000	USD
CY2016Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	146000	USD
CY2016Q4	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-3229000	USD
CY2016Q4	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	89109000	shares
CY2015Q4	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	77326000	shares
CY2016Q4	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.04
CY2015Q4	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.03
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-6290000	USD
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-4051000	USD
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	89109000	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	77316000	shares
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.07
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.05
CY2016Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	264000	USD
CY2016Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	292000	USD
CY2016Q2	us-gaap	Assets Current AssetsCurrent	23906000	USD
CY2016Q4	us-gaap	Assets Current AssetsCurrent	16748000	USD
CY2016Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	25574000	USD
CY2016Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	25453000	USD
CY2016Q2	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	2092000	USD
CY2016Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	1960000	USD
CY2016Q2	us-gaap	Assets Assets	51600000	USD
CY2016Q4	us-gaap	Assets Assets	44188000	USD
CY2016Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	920000	USD
CY2016Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	905000	USD
CY2016Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	1177000	USD
CY2016Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	731000	USD
CY2016Q2	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	67468000	USD
CY2016Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	67974000	USD
CY2016Q2	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-29000	USD
CY2016Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-29000	USD
CY2016Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-57591000	USD
CY2016Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-63881000	USD
CY2016Q2	us-gaap	Stockholders Equity StockholdersEquity	9937000	USD
CY2016Q4	us-gaap	Stockholders Equity StockholdersEquity	4153000	USD
CY2016Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	51600000	USD
CY2016Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	44188000	USD
CY2016Q4	us-gaap	Deferred Revenue DeferredRevenue	55000	USD
CY2016Q2	us-gaap	Deferred Revenue DeferredRevenue	24000	USD
CY2016Q4	us-gaap	Inventory Work In Process InventoryWorkInProcess	27000	USD
CY2016Q2	us-gaap	Inventory Work In Process InventoryWorkInProcess	22000	USD
CY2016Q4	us-gaap	Security Deposit SecurityDeposit	27000	USD
CY2016Q2	us-gaap	Security Deposit SecurityDeposit	28000	USD
CY2016Q4	us-gaap	Minority Interest MinorityInterest	12993000	USD
CY2016Q2	us-gaap	Minority Interest MinorityInterest	14107000	USD
CY2016Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	17146000	USD
CY2016Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	24044000	USD
CY2016Q4	us-gaap	Common Stock Value CommonStockValue	89000	USD
CY2016Q2	us-gaap	Common Stock Value CommonStockValue	89000	USD
CY2016Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2016Q2	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2016Q4	us-gaap	Capital Lease Obligations Current CapitalLeaseObligationsCurrent	176000	USD
CY2016Q2	us-gaap	Capital Lease Obligations Current CapitalLeaseObligationsCurrent	170000	USD
CY2016Q4	us-gaap	Liabilities Current LiabilitiesCurrent	1867000	USD
CY2016Q2	us-gaap	Liabilities Current LiabilitiesCurrent	2291000	USD
CY2016Q4	us-gaap	Capital Lease Obligations Noncurrent CapitalLeaseObligationsNoncurrent	25175000	USD
CY2016Q2	us-gaap	Capital Lease Obligations Noncurrent CapitalLeaseObligationsNoncurrent	25265000	USD
CY2016Q4	us-gaap	Unbilled Receivables Current UnbilledReceivablesCurrent	75000	USD
CY2016Q2	us-gaap	Unbilled Receivables Current UnbilledReceivablesCurrent	122000	USD
CY2015Q4	us-gaap	Sales Revenue Net SalesRevenueNet	134000	USD
CY2016Q4	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2351000	USD
CY2015Q4	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1684000	USD
CY2016Q4	us-gaap	Operating Expenses OperatingExpenses	3400000	USD
CY2015Q4	us-gaap	Operating Expenses OperatingExpenses	2388000	USD
CY2016Q4	us-gaap	Operating Income Loss OperatingIncomeLoss	-3325000	USD
CY2015Q4	us-gaap	Operating Income Loss OperatingIncomeLoss	-2254000	USD
CY2016Q4	us-gaap	Investment Income Interest InvestmentIncomeInterest	12000	USD
CY2015Q4	us-gaap	Investment Income Interest InvestmentIncomeInterest	2000	USD
CY2016Q4	us-gaap	Royalty Income Nonoperating RoyaltyIncomeNonoperating	4000	USD
CY2015Q4	us-gaap	Royalty Income Nonoperating RoyaltyIncomeNonoperating	6000	USD
CY2016Q4	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-467000	USD
CY2015Q4	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	8000	USD
CY2016Q4	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	-3792000	USD
CY2015Q4	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	-2245000	USD
CY2016Q4	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-563000	USD
CY2015Q4	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	0	USD
CY2016Q4	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	0	USD
CY2015Q4	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	1000	USD
CY2016Q4	us-gaap	Interest Expense InterestExpense	483000	USD
CY2015Q4	us-gaap	Interest Expense InterestExpense	0	USD
CY2016Q4	us-gaap	Profit Loss ProfitLoss	-3792000	USD
CY2015Q4	us-gaap	Profit Loss ProfitLoss	-2246000	USD
CY2015Q4	us-gaap	Net Income Loss NetIncomeLoss	-2246000	USD
CY2016Q4	us-gaap	Net Income Loss NetIncomeLoss	-3229000	USD
	us-gaap	Sales Revenue Net SalesRevenueNet	210000	USD
	us-gaap	Sales Revenue Net SalesRevenueNet	294000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-4051000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-6290000	USD
CY2016Q4	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	88000	USD
CY2016Q4	us-gaap	Depreciation Depreciation	326000	USD
CY2016Q4	us-gaap	Interest And Other Income InterestAndOtherIncome	16000	USD
CY2016Q4	ibio	Revenue From Intersegment RevenueFromIntersegment	0	USD
CY2015Q4	us-gaap	Depreciation Depreciation	1000	USD
CY2015Q4	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	91000	USD
CY2015Q4	us-gaap	Interest And Other Income InterestAndOtherIncome	8000	USD
CY2015Q4	ibio	Revenue From Intersegment RevenueFromIntersegment	0	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1869000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1255000	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	4820000	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	3106000	USD
	us-gaap	Operating Expenses OperatingExpenses	6689000	USD
	us-gaap	Operating Expenses OperatingExpenses	4361000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-6479000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-4067000	USD
	us-gaap	Investment Income Interest InvestmentIncomeInterest	25000	USD
	us-gaap	Investment Income Interest InvestmentIncomeInterest	4000	USD
	us-gaap	Royalty Income Nonoperating RoyaltyIncomeNonoperating	16000	USD
	us-gaap	Royalty Income Nonoperating RoyaltyIncomeNonoperating	12000	USD
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-925000	USD
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	16000	USD
	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	-7404000	USD
	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	-4059000	USD
	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-1114000	USD
	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	0	USD
	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	0	USD
	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-8000	USD
	us-gaap	Interest Expense InterestExpense	966000	USD
	us-gaap	Interest Expense InterestExpense	0	USD
	us-gaap	Interest And Other Income InterestAndOtherIncome	41000	USD
	ibio	Revenue From Intersegment RevenueFromIntersegment	0	USD
CY2015Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	14000	USD
CY2015Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	2201000	USD
	us-gaap	Interest And Other Income InterestAndOtherIncome	16000	USD
	ibio	Revenue From Intersegment RevenueFromIntersegment	0	USD
	ibio	Long Term Purchase Commitment Expire Date LongTermPurchaseCommitmentExpireDate	2015-12-31
CY2016Q4	us-gaap	Royalty Guarantees Commitments Amount RoyaltyGuaranteesCommitmentsAmount	200000	USD
CY2016Q2	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	6500000	shares
	dei	Document Type DocumentType	10-Q
	dei	Amendment Flag AmendmentFlag	false
	dei	Document Period End Date DocumentPeriodEndDate	2016-12-31
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2017
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q2
	dei	Entity Registrant Name EntityRegistrantName	iBio, Inc.
	dei	Entity Central Index Key EntityCentralIndexKey	0001420720
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--06-30
	dei	Entity Filer Category EntityFilerCategory	Smaller Reporting Company
	dei	Trading Symbol TradingSymbol	IBIO
CY2017Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	89109410	shares
CY2016Q4	us-gaap	Liabilities Liabilities	27042000	USD
CY2016Q2	us-gaap	Liabilities Liabilities	27556000	USD
CY2016Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2016Q2	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2016Q4	us-gaap	Accounts Payable Related Parties Current AccountsPayableRelatedPartiesCurrent	158000	USD
CY2016Q2	us-gaap	Due To Related Parties Current DueToRelatedPartiesCurrent	623000	USD
CY2016Q4	us-gaap	Preferred Stock No Par Value PreferredStockNoParValue	0
CY2016Q2	us-gaap	Accounts Payable Related Parties Current AccountsPayableRelatedPartiesCurrent	200000	USD
CY2016Q4	us-gaap	Due To Related Parties Current DueToRelatedPartiesCurrent	635000	USD
CY2016Q2	us-gaap	Preferred Stock No Par Value PreferredStockNoParValue	0
CY2016Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	1000000	shares
CY2016Q4	us-gaap	Related Party Transaction Selling General And Administrative Expenses From Transactions With Related Party RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty	187000	USD
CY2015Q4	us-gaap	Related Party Transaction Selling General And Administrative Expenses From Transactions With Related Party RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty	78000	USD
	us-gaap	Related Party Transaction Selling General And Administrative Expenses From Transactions With Related Party RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty	362000	USD
	us-gaap	Related Party Transaction Selling General And Administrative Expenses From Transactions With Related Party RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty	78000	USD
CY2016Q4	us-gaap	Interest Expense Related Party InterestExpenseRelatedParty	483000	USD
CY2016Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	1000000	shares
CY2016Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2016Q2	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2016Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2016Q2	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2016Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2016Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2016Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	175000000	shares
CY2016Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	175000000	shares
CY2016Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	89109410	shares
CY2016Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	89109410	shares
CY2016Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	89109410	shares
CY2016Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	89109410	shares
CY2016Q4	us-gaap	Related Party Transaction Expenses From Transactions With Related Party RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty	206000	USD
CY2015Q4	us-gaap	Related Party Transaction Expenses From Transactions With Related Party RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty	252000	USD
	us-gaap	Related Party Transaction Expenses From Transactions With Related Party RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty	445000	USD
	us-gaap	Related Party Transaction Expenses From Transactions With Related Party RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty	478000	USD
CY2016Q4	us-gaap	Revenue From Grants RevenueFromGrants	4000	USD
CY2015Q4	us-gaap	Revenue From Grants RevenueFromGrants	0	USD
	us-gaap	Revenue From Grants RevenueFromGrants	40000	USD
	us-gaap	Revenue From Grants RevenueFromGrants	0	USD
CY2015Q4	us-gaap	Interest Expense Related Party InterestExpenseRelatedParty	0	USD
	us-gaap	Interest Expense Related Party InterestExpenseRelatedParty	966000	USD
	us-gaap	Interest Expense Related Party InterestExpenseRelatedParty	0	USD
	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	506000	USD
	us-gaap	Gain Loss On Disposition Of Intangible Assets GainLossOnDispositionOfIntangibleAssets	0	USD
	us-gaap	Gain Loss On Disposition Of Intangible Assets GainLossOnDispositionOfIntangibleAssets	-17000	USD
	us-gaap	Nature Of Operations NatureOfOperations	<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="center"></div> <table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; LINE-HEIGHT: 115%; WIDTH: 100%; BORDER-COLLAPSE: collapse; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid" border="0" cellspacing="0" cellpadding="0" width="100%"> <tr> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 0.25in; PADDING-RIGHT: 0.8pt; PADDING-TOP: 0in" valign="top" width="24"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 12pt"> <b><font style="FONT-SIZE: 10pt">1.</font></b></div> </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; PADDING-RIGHT: 0.8pt; PADDING-TOP: 0in" valign="top"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 12pt" align="justify"><b><font style="FONT-SIZE: 10pt">Nature of Business</font></b></div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">    </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">iBio, Inc. and Subsidiaries (“iBio” or the “Company”) is a biotechnology company focused on the commercialization of its proprietary plant-based protein expression technologies for vaccines and therapeutic proteins and on developing and commercializing select biopharmaceutical product candidates. The advantages of iBio’s technology include reduced production time, capital and operating costs for biopharmaceuticals and the ability to manufacture therapeutic proteins that are difficult or commercially infeasible to produce with conventional methods.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">iBio was established as a public company in August 2008 as the result of a spin-off from Integrated BioPharma, Inc. The Company operates in one business segment under the direction of its Executive Chairman. The Company’s wholly-owned and majority-owned subsidiaries are as follows:</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">iBioDefense Biologics LLC (“iBioDefense”) iBioDefense, a wholly-owned subsidiary, is a Delaware limited liability company formed in July 2013 to explore development and commercialization of defense-specific applications of the Company’s proprietary technology. iBioDefense did not commence any business activities and was dissolved on June 10, 2016.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">iBio Peptide Therapeutics LLC (“iBio Peptide”) iBio Peptide, a wholly-owned subsidiary, is a Delaware limited liability company formed in November 2013. iBio Peptide did not commence any business activities and was dissolved on June 9, 2016.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt"> </font></div> <font style="FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">iBIO DO BRASIL BIOFARMACÊUTICA LTDA. (“iBio Brazil”) iBio Brazil is a subsidiary organized in Brazil in which the Company has a <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 99</font>% interest. iBio Brazil was formed to manage and expand the Company’s business activities in Brazil. The activities of iBio Brazil are intended to include coordination and expansion of the Company’s existing relationship with Fundacao Oswaldo Cruz/Fiocruz (“Fiocruz”) beyond the current Yellow Fever Vaccine program (see Note 7) and development of additional products with private sector participants for the Brazilian market. iBio Brazil commenced operations during the first quarter of the fiscal year ended June 30, 2015.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">iBio Manufacturing LLC (“iBio Manufacturing”) iBio Manufacturing, a wholly-owned subsidiary, is a Delaware limited liability company formed in November 2015. iBio Manufacturing has not commenced any activities to date.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">iBio CMO LLC (“iBio CMO”) iBio CMO is a Delaware limited liability company formed on December 16, 2015 to develop and manufacture plant-made pharmaceuticals. As of December 31, 2015, the Company owned <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 100</font>% of iBio CMO. On January 13, 2016, the Company entered into a contract manufacturing joint venture with an affiliate of Eastern Capital Limited (“Eastern”), a stockholder of the Company (the “Eastern Affiliate”). The Eastern Affiliate contributed $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">15</font> million in cash for a <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 30</font>% interest in iBio CMO. The Company retained a <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 70</font>% interest in iBio CMO and contributed a royalty bearing license which grants iBio CMO a non-exclusive license to use the Company’s proprietary technologies for research purposes and an exclusive U.S. license for manufacturing purposes. The Company retained the exclusive right to grant product licenses to those who wish to sell or distribute products made using the Company’s technologies.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">iBio CMO’s operations take place in Bryan, Texas in a facility controlled by another affiliate of Eastern (the “Second Eastern Affiliate”) as sublandlord. The facility is a <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 139,000</font> square foot Class A life sciences building on the campus of Texas A&M University, designed and equipped for plant-made manufacture of biopharmaceuticals. The Second Eastern Affiliate granted iBio CMO a <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 34</font>-year sublease for the facility as well as certain equipment (see Note 8). Commercial operations commenced in January 2016. iBio CMO expects to operate on the basis of three parallel lines of business: (1) Development and manufacturing of third party products; (2) Development and production of iBio’s proprietary product(s) for treatment of fibrotic diseases; and (3) Commercial technology transfer services. </font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
	us-gaap	Use Of Estimates UseOfEstimates	<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><i><font style="FONT-SIZE: 10pt">Use of Estimates</font></i></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect reported amounts of assets and liabilities, disclosures of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting period. These estimates include the valuation of intellectual property, legal and contractual contingencies and share-based compensation. Although management bases its estimates on historical experience and various other assumptions that are believed to be reasonable under the circumstances, actual results could differ from these estimates.</font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
CY2016Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	26707000	USD
CY2016Q2	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	26179000	USD
CY2016Q4	us-gaap	Capital Leases Lessee Balance Sheet Assets By Major Class Accumulated Deprecation CapitalLeasesLesseeBalanceSheetAssetsByMajorClassAccumulatedDeprecation	1193000	USD
CY2016Q2	us-gaap	Capital Leases Lessee Balance Sheet Assets By Major Class Accumulated Deprecation CapitalLeasesLesseeBalanceSheetAssetsByMajorClassAccumulatedDeprecation	571000	USD
CY2016Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment Excluding Capital Leased Assets AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipmentExcludingCapitalLeasedAssets	61000	USD
CY2016Q2	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment Excluding Capital Leased Assets AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipmentExcludingCapitalLeasedAssets	34000	USD
CY2016Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	1254000	USD
CY2016Q2	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	605000	USD
CY2016Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	3449000	USD
CY2016Q2	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	3273000	USD
CY2016Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	5409000	USD
CY2016Q2	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	5365000	USD
CY2016Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant	2700000	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	0
	us-gaap	Capital Leases Income Statement Interest Expense CapitalLeasesIncomeStatementInterestExpense	0	USD
CY2016Q2	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	4043000	USD
CY2015Q4	us-gaap	Assets Assets	9416000	USD
CY2015Q4	us-gaap	Gain Loss On Disposition Of Intangible Assets GainLossOnDispositionOfIntangibleAssets	-17000	USD
CY2016Q4	us-gaap	Gain Loss On Disposition Of Intangible Assets GainLossOnDispositionOfIntangibleAssets	0	USD
CY2015Q2	ibio	Registration Common Stock RegistrationCommonStock	15000000	USD
	ibio	Capital Lease Obligation Description CapitalLeaseObligationDescription	The base rent under the sublease will be increased by any increase in the base rent under the ground lease as a result of such adjustments. In addition to the base rent, iBio CMO is required to pay, for each calendar year during the term, a portion of the total gross sales for products manufactured or processed at the facility, equal to 7% of the first $5,000,000 of gross sales, 6% of gross sales between $5,000,001 and $25,000,000, 5% of gross sales between $25,000,001 and $50,000,000, 4% of gross sales between $50,000,001 and $100,000,000, and 3% of gross sales between $100,000,001 and $500,000,000. However, if for any calendar year period from January 1, 2018 through December 31, 2019, iBio CMO’s applicable gross sales are less than $5,000,000, or for any calendar year period from and after January 1, 2020, its applicable gross sales are less than $10,000,000, then iBio CMO is required to pay the amount that would have been payable if it had achieved such minimum gross sales and shall pay no less than the applicable percentage for the minimum gross sales for each subsequent calendar year. Percentage rent amounted to approximately $29,000 and $45,000 for the three and six months ended December 31, 2016, respectively. There was no percentage rent for 2015.
	ibio	Unpaid Intangible Assets Included In Accounts Payable UnpaidIntangibleAssetsIncludedInAccountsPayable	197000	USD
	ibio	Unpaid Intangible Assets Included In Accounts Payable UnpaidIntangibleAssetsIncludedInAccountsPayable	40000	USD
	ibio	Capital Expenditures Incurred Payments Made CapitalExpendituresIncurredPaymentsMade	71000	USD
	ibio	Capital Expenditures Incurred Payments Made CapitalExpendituresIncurredPaymentsMade	0	USD
	ibio	Unpaid Fixed Assets Included In Accounts Payable UnpaidFixedAssetsIncludedInAccountsPayable	61000	USD
	ibio	Unpaid Fixed Assets Included In Accounts Payable UnpaidFixedAssetsIncludedInAccountsPayable	0	USD

Files In Submission

Name	View Source	Status
0001144204-17-010136-index-headers.html	Edgar Link	pending
0001144204-17-010136-index.html	Edgar Link	pending
0001144204-17-010136.txt	Edgar Link	pending
0001144204-17-010136-xbrl.zip	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
ibio-20161231.xml	Edgar Link	completed
ibio-20161231.xsd	Edgar Link	pending
ibio-20161231_cal.xml	Edgar Link	unprocessable
ibio-20161231_def.xml	Edgar Link	unprocessable
ibio-20161231_lab.xml	Edgar Link	unprocessable
ibio-20161231_pre.xml	Edgar Link	unprocessable
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
v459672_10q.htm	Edgar Link	pending
v459672_ex31-1.htm	Edgar Link	pending
v459672_ex31-2.htm	Edgar Link	pending
v459672_ex32-1.htm	Edgar Link	pending
v459672_ex32-2.htm	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$IBIO
iBio, Inc. Stock $ibio

2017 Q1 Form 10-Q Financial Statement

#000114420417010136 Filed on February 21, 2017

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$IBIO iBio, Inc. Stock $ibio

2017 Q1 Form 10-Q Financial Statement

#000114420417010136 Filed on February 21, 2017

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$IBIO
iBio, Inc. Stock $ibio